ENTITY

Newron Pharmaceuticals (NWRN SW)

31
Analysis
Health CareItaly
Newron Pharmaceuticals SpA is a research and development biopharmaceutical company. The Company focuses on and develops therapies for the Central Nervous System (CNS) in cases such as Parkinson's disease, neuropathic low back pain and other cognitive disorders.
more
Refresh
22 Sep 2020 16:26Issuer-paid

Newron Pharmaceuticals - Evenamide trial progressing well

Newron has reported excellent, fast recruitment for the Phase II study of its novel schizophrenia drug, Evenamide, due to report in Q121. Newron...

Share
26 Aug 2020 14:30Issuer-paid

Newron Pharmaceuticals - Evenamide safety trial underway

Newron is focusing on its novel schizophrenia drug, Evenamide, and on a further Xadago study. The Evenamide preclinical studies required by the FDA...

Share
22 May 2020 22:04Issuer-paid

Newron Pharmaceuticals - Evenamide focus, Supernus to sell Xadago in US

Given that sarizotan did not meet the primary or any secondary endpoints in the pivotal Rett syndrome STARS study, Newron is focusing on its novel...

Share
05 May 2020 14:20Issuer-paid

Newron Pharmaceuticals - Sarizotan fails to shine

On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary...

Share
26 Mar 2020 16:52Issuer-paid

Newron Pharmaceuticals - Seeing STARS

The statistical analysis plan for the pivotal STARS trial of sarizotan for symptomatic treatment of Rett syndrome should be FDA approved soon. This...

Share
x